Loading institutional data...
Loading institutional data...
Held by 333 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $68.00 today, the market must believe free cash flow compounds -7.2%/yr for a decade (off $702M normalized FCF).
2-stage DCF · 0.08B shares · net debt -$698M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B 100.0% | $806.8M 100.0% | $937.8M 100.0% | $698.8M 100.0% | $538.6M 100.0% | $380.8M 100.0% | $307.0M 100.0% | $264.7M 100.0% | $194.4M 100.0% | $82.7M 100.0% |
| Cost of Revenue | — | — | — | — | — | — | $12.1M 4.0% | $12.7M 4.8% | $4.6M 2.4% | $0 0.0% |
| Cost of Products | — | — | — | — | — | — | — | $12.7M 4.8% | $4.6M 2.4% | $0 0.0% |
| Research & Development | $455.2M 26.3% | $534.5M 66.2% | $666.6M 71.1% | $651.5M 93.2% | $540.7M 100.4% | $477.6M 125.4% | $257.5M 83.9% | $172.0M 65.0% | $117.5M 60.4% | $117.6M 142.2% |
| Selling, General & Admin | $347.1M 20.1% | $300.9M 37.3% | $332.5M 35.5% | $326.0M 46.7% | $285.8M 53.1% | $245.2M 64.4% | $202.5M 66.0% | $153.5M 58.0% | $121.3M 62.4% | $97.1M 117.4% |
| Total Operating Expenses | $863.7M 49.9% | $1.11B 137.5% | $1.38B 146.9% | $1.15B 164.0% | $913.0M 169.5% | $812.5M 213.4% | $548.1M 178.6% | $380.4M 143.7% | $258.7M 133.1% | $214.8M 259.7% |
| Operating Income | $866.9M 50.1% | -$302.6M -37.5% | -$439.5M -46.9% | -$447.4M -64.0% | -$374.4M -69.5% | -$431.8M -113.4% | -$241.2M -78.6% | -$115.7M -43.7% | -$64.3M -33.1% | -$132.1M -159.7% |
| Other Income (Expense), net | -$18.1M -1.0% | $6.5M 0.8% | $10.1M 1.1% | -$49.2M -7.0% | -$57.9M -10.7% | $85.2M 22.4% | $13.7M 4.5% | $129K 0.0% | -$1.3M -0.7% | -$1.2M -1.5% |
| Pretax Income | $696.6M 40.3% | -$363.1M -45.0% | -$696.1M -74.2% | -$587.5M -84.1% | -$518.3M -96.2% | -$402.9M -105.8% | -$239.9M -78.2% | -$128.1M -48.4% | -$77.7M -40.0% | -$141.5M -171.1% |
| Income Tax Expense | $14.0M 0.8% | $176K 0.0% | -$69.5M -7.4% | -$28.5M -4.1% | $5.6M 1.0% | $35.2M 9.3% | $11.7M 3.8% | -$29K -0.0% | $1.3M 0.7% | $569K 0.7% |
| Net Income | $683.0M 39.5% | -$363.3M -45.0% | -$626.6M -66.8% | -$559.0M -80.0% | -$523.9M -97.3% | -$438.2M -115.1% | -$251.6M -82.0% | -$128.1M -48.4% | -$79.0M -40.6% | -$142.1M -171.8% |
| Per Share | ||||||||||
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | — |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | — | — | — |
| Weighted Avg Shares (Basic) | 79.5M | 76.8M | 74.8M | 71.7M | 70.5M | 66.0M | 58.9M | — | — | — |
| Weighted Avg Shares (Diluted) | 88.3M | 76.8M | 74.8M | 71.7M | 70.5M | 66.0M | 58.9M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $702M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 839%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash of $985M fully covers short-term debt of $287M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 13-yr range · 8th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 4.8 | 4.0 | — | — | — | — | — | — |
| R&D | 65.0 | 83.9 | 125.4 | 100.4 | 93.2 | 71.1 | 66.2 | 26.3 |
| SG&A | 58.0 | 66.0 | 64.4 | 53.1 | 46.7 | 35.5 | 37.3 | 20.1 |
| Operating Income | -43.7 | -78.6 | -113.4 | -69.5 | -64.0 | -46.9 | -37.5 | 50.1 |
| Income Tax | -0.0 | 3.8 | 9.3 | 1.0 | -4.1 | -7.4 | 0.0 | 0.8 |
| Net Income | -48.4 | -82.0 | -115.1 | -97.3 | -80.0 | -66.8 | -45.0 | 39.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PTCT: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PTCT | $5.5B | 8.7× | 5.3× | 3.2× | 115% | — | 39.4% | -332% | 839% | 0.3× | 333 |
Peers = companies sharing PTCT's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.